Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scyllo-inositol - Transition Therapeutics Ireland

Next Previous
X
Search
Drug Profile

Scyllo-inositol - Transition Therapeutics Ireland

Alternative Names: AZD-103; ELND-005; Quercinitol; Scyllitol; Scyllocyclohexanehexol; Scylloinositol

Latest Information Update: 01 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transition Therapeutics
  • Developer Speranza Therapeutics; Transition Therapeutics Ireland
  • Class Antidementias; Cyclohexanols; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Down syndrome
  • Discontinued Bipolar disorders

Most Recent Events

  • 30 Jan 2018 Scyllo-inositol is still at phase II/III for Alzheimer's disease (for the treatment of agitation and aggression) in Canada, Spain, USA and United Kingdom and at phase II for Down syndrome in USA (PO) (Transition Therapeutics pipeline, January 2018)
  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 15 Oct 2015 Efficacy and safety data from the phase II/III HARMONY AD trial released by Transition Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top